...
首页> 外文期刊>Kidney international. >Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: A prospective, randomized clinical trial
【24h】

Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: A prospective, randomized clinical trial

机译:使用抗生素锁定技术预防未充气的血液透析导管相关菌血症:一项前瞻性随机临床试验

获取原文
           

摘要

As a result of the high rate of infection, the NKF-K/DOQI guidelines recommended that an uncuffed catheter (UC) should not be used for longer than three weeks. However, the findings of the Dialysis Outcomes and Practice Patterns Study recognized that 48% of new hemodialysis patients in the US and 75% in Europe used UC for temporary access during arteriovenous fistula or graft maturation. The antibiotic lock technique (ALT) has been recommended to prevent catheter-related bacteremia (CRB). Here, we prospectively evaluated the efficacy of catheter-restricted filling using an antibiotic lock solution in preventing CRB. A total of 120 new hemodialysis patients requiring a temporary catheter while waiting for placement and maturation of an arteriovenous fistula or graft were enrolled in this study. Patients with a UC were randomly assigned to receive either an antibiotic–heparin lock solution (antibiotic group: cefazolin 10mg/ml, gentamicin 5mg/ml, heparin 1000U/ml) or a heparin lock solution (no-antibiotic group: heparin 1000U/ml) as a catheter lock solution during the interdialytic period. The end point of the trial was CRB. CRB developed in seven (11.7%) patients in the no-antibiotic group (Staphylococcus aureus, two; Staphylococcus epidermidis, five) whereas only one patient in the antibiotic group had S. aureus bacteremia. CRB rates per 1000 catheter-days were 0.44 in the antibiotic group versus 3.12 in the no-antibiotic group (P=0.031). Kaplan–Meier analysis also showed that mean CRB-free catheter survival of 59 days (95% CI, 58–61 days) in the antibiotic group was greater than that in the no-antibiotic group (55 days; 95% CI, 50–59 days). The results suggest that ALT may be a beneficial means of reducing the CRB rate in hemodialysis patients with UC.
机译:由于感染率很高,NKF-K / DOQI指南建议不要将无袖导管(UC)使用超过三周。但是,“透析结果和实践模式研究”的发现认识到,美国48%的新血液透析患者和75%的欧洲新血液透析患者在动静脉瘘或移植物成熟期间使用UC进行临时进入。建议使用抗生素锁定技术(ALT)来预防导管相关菌血症(CRB)。在这里,我们前瞻性地评估了使用抗生素锁定溶液的导管限制填充在预防CRB中的功效。本研究共纳入120名新的血液透析患者,这些患者在等待动静脉瘘管或移植物的放置和成熟时需要临时导管。 UC患者被随机分配接受抗生素-肝素锁定溶液(抗生素组:头孢唑啉10mg / ml,庆大霉素5mg / ml,肝素1000U / ml)或肝素锁定溶液(非抗生素组:肝素1000U / ml )作为透析间期的导管锁定溶液。试验的终点是CRB。非抗生素组中有七名(11.7%)患者出现CRB(金黄色葡萄球菌,两名;表皮葡萄球菌,五名),而抗生素组中只有一名患有金黄色葡萄球菌菌血症。抗生素组每1000个导管日的CRB率为0.44,而非抗生素组为3.12(P = 0.031)。 Kaplan–Meier分析还显示,抗生素组的无CRB导管平均生存期为59天(95%CI,58-61天)比无抗生素组(55天; 95%CI, 50-59天)。结果表明,ALT可能是降低UC血液透析患者CRB率的有益手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号